19 June 2013
Keywords: novartis, unveils, first, data, cox-2, drug, prexige
Article | 27 May 2002
Novartis' eagerly-anticipated entrant into the COX-2 inhibitor sector,Prexige (lumiracoxib/COX189), was the subject of three studies at the
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 May 2002
29 April 2002
6 May 2002
© 2013 thepharmaletter.com